Statements (26)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Genentech
|
| gptkbp:activities |
IL-1 receptor antagonist
|
| gptkbp:approves |
gptkb:2001
gptkb:FDA |
| gptkbp:class |
interleukin inhibitors
|
| gptkbp:clinical_trial |
Phase III trials
~95% |
| https://www.w3.org/2000/01/rdf-schema#label |
Kineret
|
| gptkbp:ingredients |
C14 H18 N4 O5 S
anakinra |
| gptkbp:is_atype_of |
L04 A C02
|
| gptkbp:is_used_for |
gptkb:healthcare_organization
gptkb:rheumatoid_arthritis gout |
| gptkbp:legal_issue |
prescription only
|
| gptkbp:manager |
subcutaneous injection
|
| gptkbp:manufacturer |
gptkb:Amgen
|
| gptkbp:marketed_as |
gptkb:Kineret
|
| gptkbp:side_effect |
headache
nausea increased risk of infections injection site reactions |
| gptkbp:type_of |
144460-73-1
|
| gptkbp:weight |
334.38 g/mol
|